Anlon Healthcare to Acquire 56.67% Stake in Bizotic Lifescience for Rs.3,79,69,500

Anlon Healthcare Limited has entered into a Share Purchase Agreement (SPA) with Bizotic Lifescience Private Limited for the acquisition of 56.67% shareholding of the Target Company. The Target Company is an Indian private limited company, incorporated on April 17, 2015, and is engaged in the business of manufacturing, supplying, and exporting pharmaceutical drugs and intermediates, industrial and fine chemicals, and active pharmaceutical ingredients (API). The acquisition will enable Anlon Healthcare to augment its existing manufacturing capacity, provide immediate availability of validated production lines and established process systems, and support earlier revenue contribution. The transaction is expected to provide faster operational readiness, reduce regulatory and execution-related uncertainties, and strengthen the Company’s operational efficiency and long-term competitiveness. The acquisition is subject to completion of certain customary closing conditions under the SPA and is expected to be completed within 3 months from the date of signing of the SPA. The consideration would be paid in cash, with the cost of acquisition being Rs.3,79,69,500 and the price at which shares are acquired being 25,50,000 equity shares at a price of Rs.14.89/- each, aggregating Rs.3,79,69,500/-.